This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider.
Lin Chang, MD: Hello. I'm Dr Lin Chang. Welcome to Medscape's InDiscussion series on irritable bowel syndrome (IBS). Today we'll be discussing the role of the microbiome in IBS and the related topics of postinfection IBS, post-COVID IBS, and long-COVID IBS with Dr Madhu Grover. Dr Grover is an associate professor of medicine and physiology and consultant in the division of gastroenterology and hepatology in the department of internal medicine at Mayo Clinic in Rochester, Minnesota. Welcome to InDiscussion. Madhu, thanks so much for joining us today. It's so great to have you. You're an expert in this field, and I'm sure our listeners will love to hear what you have to say and your expertise on this complicated topic of IBS.
Madhusudan Grover, MBBS: Thanks for having me.
Chang: How did you become interested in IBS?
Grover:This dates back now almost 15 years ago. I was an internal medicine resident, and I chose to work with Doug Drossman and Bill Whitehead at the University of North Carolina (UNC). I was interested in neurogastroenterology — the biopsychosocial context addressing how we think about these disorders and how we address and treat them.
